Cold Genesys Inc., a Santa Ana, CA-based clinical-stage oncolytic immunotherapy company, completed a $10m Series B financing.
The round was co-led by Ally Bridge Group and WI Harper Group with participation from Whitesun Healthcare Ventures and Song Hong Fang. In conjunction with the financing, Arthur Kuan, a founding member of Ally Bridge Group and Chief Operating Officer of Cold Genesys, will join Cold Genesys’s Board of Directors.
The company intends to use the funds to advance its investigational oncolytic immunotherapy CG0070 in a pivotal study (BOND II) that is currently enrolling 122 patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have failed first-line BCG therapy as well as to develop the combination of CG0070 with immune checkpoint modulators in multiple Phase I/II studies for different solid tumor indications.
Led by Alex Yeung, MBBS, Chief Executive Officer and Chairman, Cold Genesys is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer.
It is now advancing CG0070, an investigational oncolytic immunotherapy based on a modified common cold virus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells.